• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CytoMed Therapeutics Limited - Ordinary Shares (NQ:GDTC)

    0.7990 -0.0910 (-10.22%)
    Delayed Quote Updated: 1:30 PM EDT, Oct 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about CytoMed Therapeutics Limited - Ordinary Shares

    < Previous 1 2 Next >
    News headline image
    CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector
    Via Get News
    News headline image
    CytoMed Therapeutics Ltd (NASDAQ: GDTC) – A Rising Star in Singapore’s Cancer Biotechnology Sector
    Via Get News
    News headline image
    CytoMed, a Singapore Biotech, Revolutionizes Cancer Treatment Using Donor Immune Cells
    Via Get News
    News headline image
    CytoMed Therapeutics Ltd – A Rising Star in Singapore’s Cancer Biotechnology Sector
    Via Get News
    News headline image
    CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
    Completion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary, LongevityBank Pte Ltd 
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
    Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technology 
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration
    The global population is rapidly aging. According to the World Population Prospects 2022 published by the United Nations, there were 
    Via Spotlight Growth
    News headline image
    CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
    Via ACCESSWIRE
    News headline image
    CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
    CytoMed diversifies into regenerative medicine 
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
    The Company now has exclusive rights to a Malaysia, US and China patent 
    From CYTOMED THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Singapore’s Journey to Becoming a Biotech Powerhouse
    Singapore's Biotech Vision: From 2000 Onwards In 2000, Singapore embarked on an ambitious mission to establish itself as a leading 
    Via Spotlight Growth
    Topics Economy
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.